ASC60

ASC60 (Ascletis BioScience): sourced facts only. name: "Here we report the in vivo efficacy data of ASC60, a small molecular FASN inhibitor, either as a single agent or in combination with mouse programmed cell death-1 (mPD-1) antibody in two tumor mouse models." [DOI:10.1158/1538-7445.am2022-5466]; target: "Here we report the in vivo efficacy data of ASC60, a small molecular FASN inhibitor, either as a single agent or in combination with mouse programmed cell death-1 (mPD-1) antibody in two tumor mouse models." [DOI:10.1158/1538-7445.am2022-5466]; developer: "1Ascletis BioScience Co., Ltd., Hangzhou, China." [DOI:10.1158/1538-7445.am2022-5466]; modality: "Here we report the in vivo efficacy data of ASC60, a small molecular FASN inhibitor, either as a single agent or in combination with mouse programmed cell death-1 (mPD-1) antibody in two tumor mouse models." [DOI:10.1158/1538-7445.am2022-5466]; stage: "In the MC38 colon cancer mouse model, mice treated with ASC60 (60 or 100 mg/kg) in combination with mPD-1 antibody showed higher TGI values compared to those treated with mPD-1 alone (91.86%, 99.88% vs 89.84%) on Day 13, indicating combination with ASC60 would enhance the antitumor activity of mPD-1 antibody." [DOI:10.1158/1538-7445.am2022-5466]